Gena Wang
Stock Analyst at Barclays
(2.10)
# 1,554
Out of 4,667 analysts
187
Total ratings
35.43%
Success rate
-4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Maintains: Underweight | $3 → $4 | $5.79 | -30.92% | 8 | Nov 15, 2024 | |
| BLUE bluebird bio | Maintains: Overweight | $4 → $2 | $0.30 | +560.07% | 9 | Nov 15, 2024 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $3 → $9 | $1.95 | +361.54% | 3 | Nov 14, 2024 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $43 → $45 | $41.96 | +7.25% | 13 | Nov 14, 2024 | |
| MRNA Moderna | Maintains: Overweight | $125 → $111 | $36.94 | +200.49% | 7 | Nov 8, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $76 → $55 | $13.12 | +319.21% | 6 | Nov 8, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $59 → $55 | $47.26 | +16.38% | 14 | Nov 6, 2024 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $7 → $5 | $2.41 | +107.47% | 8 | Nov 5, 2024 | |
| CLLS Cellectis | Maintains: Overweight | $7 → $5 | $1.91 | +161.78% | 3 | Nov 5, 2024 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Equal-Weight | $7 → $8 | $7.30 | +9.59% | 9 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $6.74 | +285.76% | 5 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $248.79 | +32.24% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $62.56 | +37.47% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $63 | $43.65 | +44.33% | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $15 | $4.96 | +202.42% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $226 → $203 | $110.86 | +83.11% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $31 | $24.49 | +26.58% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $9.63 | +419.21% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $46.40 | +74.57% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $472 → $509 | $451.23 | +12.80% | 14 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $35.40 | +44.07% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.41 | +435.08% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $40.14 | +134.18% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $14.55 | -38.14% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $16.17 | +54.61% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $5.82 | +209.28% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $6.90 | +15.94% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $2.84 | +216.90% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.75 | +4,682.61% | 1 | Jan 6, 2017 |
Kodiak Sciences
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $5.79
Upside: -30.92%
bluebird bio
Nov 15, 2024
Maintains: Overweight
Price Target: $4 → $2
Current: $0.30
Upside: +560.07%
Sangamo Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $9
Current: $1.95
Upside: +361.54%
PTC Therapeutics
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $43 → $45
Current: $41.96
Upside: +7.25%
Moderna
Nov 8, 2024
Maintains: Overweight
Price Target: $125 → $111
Current: $36.94
Upside: +200.49%
Intellia Therapeutics
Nov 8, 2024
Maintains: Overweight
Price Target: $76 → $55
Current: $13.12
Upside: +319.21%
CRISPR Therapeutics AG
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $59 → $55
Current: $47.26
Upside: +16.38%
Editas Medicine
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.41
Upside: +107.47%
Cellectis
Nov 5, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $1.91
Upside: +161.78%
BioCryst Pharmaceuticals
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $7.30
Upside: +9.59%
Nov 4, 2024
Maintains: Overweight
Price Target: $28 → $26
Current: $6.74
Upside: +285.76%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $248.79
Upside: +32.24%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $62.56
Upside: +37.47%
Aug 28, 2024
Initiates: Overweight
Price Target: $63
Current: $43.65
Upside: +44.33%
Aug 14, 2024
Maintains: Overweight
Price Target: $18 → $15
Current: $4.96
Upside: +202.42%
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $110.86
Upside: +83.11%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $33 → $31
Current: $24.49
Upside: +26.58%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $9.63
Upside: +419.21%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $46.40
Upside: +74.57%
Aug 5, 2024
Downgrades: Equal-Weight
Price Target: $472 → $509
Current: $451.23
Upside: +12.80%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $35.40
Upside: +44.07%
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $8.41
Upside: +435.08%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $40.14
Upside: +134.18%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $14.55
Upside: -38.14%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $16.17
Upside: +54.61%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $5.82
Upside: +209.28%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $6.90
Upside: +15.94%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $2.84
Upside: +216.90%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.75
Upside: +4,682.61%